pemirolast potassium - Profile

What are the generic drug sources for pemirolast potassium and what is the scope of patent protection?

Pemirolast potassium is the generic ingredient in one branded drug marketed by Santen and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for pemirolast potassium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for pemirolast potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santen	ALAMAST	pemirolast potassium	SOLUTION/DROPS;OPHTHALMIC	021079-001	Sep 24, 1999		DISCN	No	No

Expired US Patents for pemirolast potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Santen	ALAMAST	pemirolast potassium	SOLUTION/DROPS;OPHTHALMIC	021079-001	Sep 24, 1999

Investment Scenario and Fundamentals Analysis for Pemirolast Potassium

Last updated: February 3, 2026

Overview

Pemirolast potassium is an anti-allergic agent used primarily for allergic conjunctivitis. It functions as a mast cell stabilizer, preventing the release of histamine and other mediators responsible for allergic reactions. The drug is marketed under various brand names, with limited current usage but potential growth in allergy treatment markets. Its patent status, regulatory landscape, and competitive environment influence its investment prospects.

Market Landscape

• Indications: Allergic conjunctivitis, allergic rhinitis (off-label in some markets)
• Market Size: Estimated global allergic conjunctivitis market valuation at approximately $600 million in 2022, with projections of a compound annual growth rate (CAGR) around 4% until 2027 [1].
• Key Players: Allergan (now regulated by AbbVie), Novartis, and independently marketed generics
• Market Drivers: Rising prevalence of allergic conditions, increased awareness, and demand for targeted therapies

Regulatory Status

• FDA: Approved for allergic conjunctivitis, marketed as Alamast andothers.
• EMA: Similar approvals in Europe, with some regions handling it as an over-the-counter drug.
• Patent Landscape: Patents expired in the U.S. and Europe approximately between 2015 and 2018, leading to increased generic competition and price erosion.

Fundamentals and Investment Risks

1. Patent and Exclusivity: The expiration of patents in key markets reduces market exclusivity, pressuring pricing power and margins. Potential pipeline IP filings may offer strategic value but face generic threats.

2. Market Penetration: Limited adoption beyond allergy indications constrains growth. Expanding indications could improve revenue but depends on clinical validation.

3. Development and Regulatory Costs: Pemirolast is off-patent; future development relies on lifecycle management, including new formulation approvals or combination products, which entail significant R&D investments.

4. Pricing and Reimbursement: As a generic, pricing is competitive. Reimbursement policies favor cost-effective allergy treatments, limiting revenue potential.

5. Manufacturing and Supply Chain: Established APIs and inactive ingredients reduce manufacturing costs. Investment risk centers on supply disruptions or regulatory compliance costs.

6. Competitive Landscape: The presence of multiple generics diminishes market share for any single manufacturer. Emerging therapies with different mechanisms may threaten usage.

Investment Scenarios

• Conservative: Maintain a position based on its established market, with expectations of revenue stabilization post-patent expiration. Risk of flat growth remains high.
• Aggressive: Invest into pipeline or combination therapies integrating pemirolast to access new markets or higher-margin formulations. High risk due to uncertain clinical trial outcomes.
• Speculative: Focus on emerging indications or formulations where patent protection or exclusivity could be secured, though such opportunities are currently limited.

Financial Metrics and Valuation

• Historical Sales: Approximate global sales of $150-200 million pre-patent expiry, declining as generics entered.
• Cost of Goods Sold (COGS): Estimated around 15–20% of sales, benefiting from mature manufacturing processes.
• Profitability: Margins declined post-patent expiry; generic environment exerts downward pressure.
• Market Share: Dominated by a handful of generic manufacturers, with top players holding less than 20% each.

Potential for Growth

• Limited growth prospects within the existing indication unless novel formulations or combined therapies gain regulatory approval.
• Portfolio diversification into allergy-related formulations or delivery systems could provide incremental gains.

Strategic Considerations for Investors

• Risk of Obsolescence: High, due to patent expiry and generic competition.
• In-licensing or Acquisition: Potential to acquire novel formulations or pipeline assets that leverage pemirolast's mechanism.
• Partnerships: Collaborations with specialty clinics or ophthalmology networks could boost uptake.

Key Takeaways

• Pemirolast potassium is a mature, off-patent drug with declining revenues in its core markets.
• The drug faces intense generic competition, limiting upside unless new indications or formulations are introduced.
• The primary value lies in its potential as part of combination therapies or in niche markets.
• Investment risk remains high without significant pipeline development or market expansion.
• Healthcare policy shifts and reimbursement trends actively influence viability.

FAQs

1. What are the main competitors to pemirolast potassium?
   The main competitors are other mast cell stabilizers and antihistamines approved for allergic conjunctivitis, including olopatadine and ketotifen.

2. Is there potential for new patent protection?
   New formulation patents (e.g., sustained-release versions) may offer periods of exclusivity but face hurdles due to the drug’s age and existing patents.

3. What are the clinical prospects for expanding pemirolast’s indications?
   Limited. Current data is primarily for allergy treatment; expanding to other allergic conditions requires substantial clinical trial investment with uncertain outcomes.

4. How does the patent status affect the investment outlook?
   Patent expiration generally leads to revenue decline and increased generic competition, reducing profit margins and making the asset less attractive.

5. Are there any major regulatory hurdles for future development?
   Regulatory agencies require demonstration of safety and efficacy for new indications or formulations, which can be costly and time-consuming with uncertain success.

---

References

[1] MarketWatch. "Global Allergic Conjunctivitis Market Size, Share, Growth and Forecast 2022-2027."